Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Andre Bubendorf is active.

Publication


Featured researches published by Andre Bubendorf.


Biochemical Pharmacology | 1998

A Comparison and Analysis of Several Ways to Promote Haematin (Haem) Polymerisation and an Assessment of Its Initiation In Vitro

Arnulf Dorn; Sudha Rani Vippagunta; Hugues Matile; Andre Bubendorf; Jonathan L. Vennerstrom; Robert G. Ridley

We compared several methods for producing haematin polymerisation at physiological temperatures (i.e., 37 degrees) and found that a trophozoite lysate-mediated reaction was inappropriate for measuring compound inhibition of haematin polymerisation. Using this method, we obtained significantly higher IC50 values (concentration inhibiting haematin polymerisation by 50%) for certain compounds than when other methods were used, including a food vacuole lysate-mediated reaction. This difference was probably due to the binding of these compounds to cytosolic parasite proteins, as proteinase K treatment of the trophozoite lysate reversed this effect. The initiation of haematin polymerisation was also investigated using several assays. It was found that haematin polymerisation occurred spontaneously, in the absence of preformed haemozoin, over a period of several days, but that the process was more rapid when an acetonitrile extract of malarial trophozoites was added. This extract contained no detectable protein, and its activity could be replicated using an extract from uninfected erythrocytes and by using lipids. We therefore postulate that no protein or parasite-specific material is absolutely required for the initiation of haematin polymerisation. The formation of beta-haematin de novo using the acetonitrile extract is more pH-dependent than the generation of newly synthesised beta-haematin from preformed haemozoin and cannot proceed much above pH = 6. We postulate that the initiation of haematin polymerisation is more sensitive to the equilibrium of haematin between its monomeric and mu-oxo dimer form and requires a higher concentration of monomer than for the elongation phase of polymerisation.


Biochemical Pharmacology | 1999

Deferoxamine: Stimulation of hematin polymerization and antagonism of its inhibition by chloroquine

Sudha Rani Vippagunta; Arnulf Dorn; Andre Bubendorf; Robert G. Ridley; Jonathan L. Vennerstrom

The iron chelator deferoxamine enhances the clearance of Plasmodium falciparum parasitemia and may be useful in drug combinations for the treatment of cerebral malaria. However, the deferoxamine-chloroquine drug combination is antagonistic, or at best additive, against P. falciparum in vitro. As chloroquine is thought to exert its antimalarial activity by interacting with hematin released from the proteolytic degradation of hemoglobin in the parasite food vacuole, we hypothesized that deferoxamine might interfere with the ability of chloroquine to inhibit hematin polymerization, since it was reported that deferoxamine interacts with hematin. Therefore, we assessed deferoxamine-hematin binding in more detail and investigated the effect of deferoxamine on hematin polymerization in the presence and absence of chloroquine. Isothermal titration calorimetry (ITC) experiments demonstrated an enthalpy-driven deferoxamine:hematin mu-oxo dimer binding with an association constant of 2.8 x 10(4) M(-1) at pH 6.5, a binding affinity 14-fold lower than that measured for chloroquine. At least two of the three hydroxamic acid functional groups of deferoxamine must be unionized for effective binding. We also discovered that deferoxamine antagonized chloroquine-mediated inhibition of hematin polymerization. Unexpectedly, deferoxamine increased the concentration of soluble forms of hematin and enhanced the rate of hematin polymerization. Deferoxamine also could initiate hematin polymerization. In contrast, chloroquine decreased the concentration of soluble forms of hematin and inhibited hematin polymerization. This work supports the postulate that initiation of hematin polymerization requires a higher concentration of soluble hematin monomer than does the elongation phase of polymerization and provides one possible explanation for the observed antagonism between deferoxamine and chloroquine against parasites in culture.


Analytica Chimica Acta | 1999

Monitoring solid phase synthesis by infrared spectroscopic techniques

Walter Huber; Andre Bubendorf; Alfred Grieder; Daniel Obrecht

The paper describes the use of attenuated total reflection fourier transform-infrared (ATR FT-IR) microspectroscopic techniques for the verification of the structure of chemical compounds synthesised on polystyrene beads in combinatorial chemistry. A six step reaction sequence is characterised completely by infrared (IR) spectroscopic investigations of single beads. Incomplete reactions or the occurrence of side products are clearly indicated. Quantitative information can be extracted with high precision using absorption bands of the polymer matrix as internal standard. Compared to other IR techniques, the ATR micro IR technique shows clear advantages with respect to sensitivity and resolution. The technique has the potential to be used for the characterisation of single beads in split and combined synthesis techniques.


Nature | 1995

Malarial haemozoin/β-haematin supports haem polymerization in the absence of protein

Arnulf Dorn; Ruedi Stoffel; Hugues Matile; Andre Bubendorf; Robert G. Ridley


Archive | 2006

New salt and polymorph of dpp-iv inhibitor

Andre Bubendorf; Olaf Grassmann; Daniel Hunziker; Holger Kuehne; Regina Moog; Urs Schwitter


Archive | 2006

New salt and polymorphs of a dpp-iv inhibitor

Stefan Abrecht; Andre Bubendorf; Stephan Goetzoe; Olaf Grassmann; Francois Montavon; Regina Moog; Franziska Rohrer; Armin Ruf; Michelangelo Scalone; Urs Schwitter; Shaoning Wang


Archive | 2004

[6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph

Andre Bubendorf; Michael Hennig; Pirmin Hidber; Goesta Rimmler; Franziska Rohrer


Archive | 2004

Polymorph of {6,7-bis(2-methoxy-ethoxy)-quinazolin-4-yl}-(3e)

Andre Bubendorf; Michael Hennig; Pirmin Hidber; Goesta Rimmler; Franziska Rohrer


Archive | 2002

Pseudopolymorphic forms of carvedilol

Andre Bubendorf; Rolf-Dieter Gabel; Michael Hennig; Siegfried Krimmer; Guenter Neugebauer; Walter Preis; Alexander Wirl


Archive | 2007

Crystalline forms glyt1

Andre Bubendorf; Annette Deynet-Vucenovic; Ralph Diodone; Olaf Grassmann; Kai Lindenstruth; Emmanuel Pinard; Franziska Rohrer; Urs Schwitter

Collaboration


Dive into the Andre Bubendorf's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge